Drug Profile

Farabursen - Novartis

Alternative Names: RGLS-8429

Latest Information Update: 08 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regulus Therapeutics
Developer Novartis
Class Antisense oligonucleotides; MicroRNAs
Mechanism of Action Gene silencing; MIRN17 microRNA expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Autosomal dominant polycystic kidney disease
New Molecular Entity No

Highest Development Phases

Phase I Autosomal dominant polycystic kidney disease

Most Recent Events

04 Nov 2025 Farabursen is still in phase I trials for Autosomal dominant polycystic kidney disease in the US
28 Jul 2025 No recent reports of development identified for phase-I development in Autosomal-dominant-polycystic-kidney-disease in USA (SC, Injection)
25 Jun 2025 Regulus Therapeutics has been acquired and merged into Novartis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com